Health ministry likely to ban over 300 combo drugs

The move, which is expected to impact top MNCs such as Abbott as well as domestic players such as Piramal, Macleods, Cipla and Lupin among others, could be challenged in the courts once again.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2OGwvSo
via IFTTT